Financial Personal
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
Data from the phase Ib Beamion LUNG-1 trial selected for late-breaking oral presentation in the Presidential Symposium at WCLC on Monday, September 9. The U.S. FDA and China’s CDE have granted zongertinib Breakthrough Therapy Designation for p
![Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio](https://img.easybranches.com/uploads/news/2024/08/boehringer-ingelheim-to-unveil-groundbreaking-oncology-research-at-wclc-demonstrating-strength-of-portfolio.jpg)
At the IASLC 2024 World Conference on Lung Cancer (WCLC) Boehringer Ingelheim will present encouraging data from across its oncology pipeline, illustrating its aspiration to transform the lives of people with cancer by delivering meaningful advances. Read More